Adenoid cystic carcinoma

EQS-News: CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

Retrieved on: 
Friday, November 11, 2022

TBINGEN, Germany/ Boston, USA November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced data from the Phase 1 expansion study of CV8102, the companys non-coding RNA candidate in oncology.

Key Points: 
  • TBINGEN, Germany/ Boston, USA November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced data from the Phase 1 expansion study of CV8102, the companys non-coding RNA candidate in oncology.
  • Preliminary results from the completed Phase 1 expansion study in patients with PD-1 refractory melanoma confirm a robust safety profile of CV8102 as a single agent and in combination with anti-PD-1 antibodies.
  • The data we collected in the heavily pretreated patients of our Phase 1 expansion study further confirm the safety and immuno-modulatory activity of CV8102, said Ulrike Gnad-Vogt, interim Chief Development Officer at CureVac.
  • The Phase 1, open-label, dose escalation and expansion study of CV8102 aims to assess safety, tolerability and efficacy of CV8102 as a single agent and in combination with licensed PD1-antibodies.

OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with pembrolizumab at SITC 2022

Retrieved on: 
Monday, November 7, 2022

The data will be featured in an oral presentation at the Society for Immunotherapy of Cancers (SITC) 37th annual meeting.

Key Points: 
  • The data will be featured in an oral presentation at the Society for Immunotherapy of Cancers (SITC) 37th annual meeting.
  • The recommended Phase 2 dose has been established at 6 mg/kg of ONC-392 in combination with 200 mg of pembrolizumab.
  • We are excited to share positive, initial results from the combination therapy portion of the PRESERVE-001 trial at the prestigious annual SITC meeting, said Yang Liu, CEO of OncoC4, Inc.
  • In addition, OncoC4 has a pipeline of first-in-class preclinical products focusing on the CD24-Siglecs cancer immune evasion pathway.

Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Retrieved on: 
Wednesday, October 12, 2022

We are excited to present updated clinical and preclinical data on RVU120 and our novel MTA-cooperative PRMT5 inhibitors at this years AACR-NCI-EORTC symposium," said Hendrik Nogai, M.D., Chief Medical Officer of Ryvu Therapeutics.

Key Points: 
  • We are excited to present updated clinical and preclinical data on RVU120 and our novel MTA-cooperative PRMT5 inhibitors at this years AACR-NCI-EORTC symposium," said Hendrik Nogai, M.D., Chief Medical Officer of Ryvu Therapeutics.
  • We are also seeing clinical benefits with disease stabilizations in patients with relapsed/refractory metastatic or advanced solid tumors.
  • Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology.
  • Ryvu Therapeutics has signed multiple partnering and licensing deals with global companies, including Merck, Menarini Group, Galapagos and Exelixis.

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

Retrieved on: 
Monday, September 12, 2022

The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.

Key Points: 
  • The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.
  • The results presented today give us increased confidence in the potential for AL102 to improve the lives of patients with desmoid tumors.
  • For more information on the RINGSIDE Phase 2/3 study with AL102 for the treatment of desmoid tumors, please visit ClinicalTrials.gov and reference Identifier NCT04871282 ( RINGSIDE ).
  • AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors ( RINGSIDE ).

Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022

Retrieved on: 
Thursday, August 25, 2022

Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.

Key Points: 
  • Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
  • Rivoceranib is co-developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (JHP) in China and by Elevar Therapeutics, Inc. globally (excluding China).
  • Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy in various solid tumor indications.
  • Elevar holds the global rights (excluding China) and has partnered for the development and marketing of rivoceranib with HLB-LS in South Korea.

Amyloid Precursor Protein Secretase Inhibitors Pipeline Market Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, August 1, 2022

This "Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Amyloid precursor protein secretase inhibitors pipeline landscape.

Key Points: 
  • This "Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Amyloid precursor protein secretase inhibitors pipeline landscape.
  • Amyloid precursor protein secretase inhibitors: Emerging Drugs Chapters
    This segment of the Amyloid precursor protein secretase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • Amyloid precursor protein secretase inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Amyloid precursor protein secretase inhibitors drugs segregated based on following parameters that define the scope of the report.
  • Amyloid precursor protein secretase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Elevar Therapeutics Shares Results of Phase 2 Rivoceranib Trial in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma

Retrieved on: 
Monday, June 6, 2022

Our entire Elevar team is greatly encouraged by these results, and we are fully focused on advancing rivoceranib through the regulatory process.

Key Points: 
  • Our entire Elevar team is greatly encouraged by these results, and we are fully focused on advancing rivoceranib through the regulatory process.
  • The positive results demonstrated in this Phase 2 trial of rivoceranib represent a vitally important step forward for them.
  • Rivoceranib, co-developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (JHP) in China and Elevar Therapeutics globally, with the exception of China.
  • Orphan drug designations have been granted in gastric cancer (U.S., EU and South Korea), adenoid cystic carcinoma (U.S.) and hepatocellular carcinoma (U.S.).

Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

Retrieved on: 
Thursday, June 2, 2022

A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website.

Key Points: 
  • A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.
  • Ayalas approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
  • AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations.

Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial

Retrieved on: 
Thursday, May 26, 2022

SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced its Phase 2 clinical trial (Study RM-202) evaluating rivoceranib, an orally administered tyrosine kinase inhibitor (TKI), demonstrated clinical effectiveness in patients with progressive recurrent or metastatic adenoid cystic carcinoma (R/M ACC). Elevar will present topline findings at the American Society of Clinical Oncology (ASCO)’s annual meeting on June 6.

Key Points: 
  • Elevar will present topline findings at the American Society of Clinical Oncology (ASCO)s annual meeting on June 6.
  • It is also gratifying that rivoceranib demonstrates a favorable safety profile, reflecting adverse events consistent with other VEGFR TKIs.
  • Rivoceranib, co-developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (JHP) in China and Elevar Therapeutics globally, with the exception of China.
  • Orphan drug designations have been granted in gastric cancer (U.S., EU and South Korea), adenoid cystic carcinoma (U.S.) and hepatocellular carcinoma (U.S.).

KIYATEC and AACR Joint Abstract at AACR Highlights Use of KIYA-PREDICT™ Drug Response Platform in ACC

Retrieved on: 
Monday, April 4, 2022

The abstract, entitled Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response, evaluates drug response using KIYATECs validated 3D-XPDX adenoid cystic carcinoma (ACC) model based on the KIYA-PREDICT drug response platform.

Key Points: 
  • The abstract, entitled Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response, evaluates drug response using KIYATECs validated 3D-XPDX adenoid cystic carcinoma (ACC) model based on the KIYA-PREDICT drug response platform.
  • KIYATEC Chief Executive Officer Matt Gevaert, Ph.D., said, We are honored to work with ACCRF for patients with this rare condition.
  • Our collaboration represents the mission of KIYATEC to disrupt and inform cancer treatment options by accurately predicting therapeutic tumor response.
  • Jeff Kaufman, Executive Director of ACCRF, said, It has been a pleasure to partner with KIYATEC to develop ex vivo ACC models for drug development and screening.